Population pharmacokinetic analysis of orally-administered ruxolitinib (INCB018424 Phosphate) in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) or post-essential thrombocythemia myelofibrosis (PET MF). [electronic resource]
Producer: 20140304Description: 721-30 p. digitalISSN:- 1552-4604
- Aged
- Clinical Trials, Phase III as Topic
- Double-Blind Method
- Female
- Humans
- Janus Kinases -- antagonists & inhibitors
- Male
- Models, Biological
- Nitriles
- Polycythemia Vera -- drug therapy
- Primary Myelofibrosis -- drug therapy
- Protein Kinase Inhibitors -- pharmacokinetics
- Pyrazoles -- administration & dosage
- Pyrimidines
- Randomized Controlled Trials as Topic
- Thrombocythemia, Essential -- drug therapy
No physical items for this record
Publication Type: Journal Article
There are no comments on this title.
Log in to your account to post a comment.